Tag Archives: harvard
They say size isn’t everything, but when it comes to delta robots it seems like it’s pretty important.
The speed and precision of these machines sees them employed in delicate pick-and-place tasks in all kinds of factories, as well as to control 3D printer heads. But Harvard researchers have found that scaling them down to millimeter scale makes them even faster and more precise, opening up applications in everything from microsurgery to manipulating tiny objects like circuit board components or even living cells.
Unlike the industrial robots you’re probably more familiar with, delta robots consist of three individually controlled arms supporting a platform. Different combinations of movements can move the platform in three directions, and a variety of tools can be attached to this platform.
The benefit of this design is that unlike a typical robotic arm, all the motors are housed at the base rather than at the joints, which reduces their mechanical complexity, but also—importantly—the weight of the arms. That means they can move and accelerate faster and with greater precision.
It’s been known for a while that the physics of these robots means the smaller you can make them, the more pronounced these advantages become, but scientists had struggled to build them at scales below tens of centimeters.
In a recent paper in the journal Science Robotics, the researchers describe how they used an origami-inspired micro-fabrication approach that relies on folding flat sheets of composite materials to create a robot measuring just 15 millimeters by 15 millimeters by 20 millimeters.
The robot dubbed “milliDelta” features joints that rely on a flexible polymer core to bend—a simplified version of the more complicated joints found in large-scale delta robots. The machine was powered by three piezoelectric actuators, which flex when a voltage is applied, and could perform movements at frequencies 15 to 20 times higher than current delta robots, with precisions down to roughly 5 micrometers.
One potential use for the device is to cancel out surgeons’ hand tremors as they carry out delicate microsurgery procedures, such as operations on the eye’s retina. The researchers actually investigated this application in their paper. They got volunteers to hold a toothpick and measured the movement of the tip to map natural hand tremors. They fed this data to the milliDelta, which was able to match the movements and therefore cancel them out.
In an email to Singularity Hub, the researchers said that adding the robot to the end of a surgical tool could make it possible to stabilize needles or scalpels, though this would require some design optimization. For a start, the base would have to be redesigned to fit on a surgical tool, and sensors would have to be added to the robot to allow it to measure tremors in real time.
Another promising application for the device would be placing components on circuit boards at very high speeds, which could prove valuable in electronics manufacturing. The researchers even think the device’s precision means it could be used for manipulating living cells in research and clinical laboratories.
The researchers even said it would be feasible to integrate the devices onto microrobots to give them similarly impressive manipulation capabilities, though that would require considerable work to overcome control and sensing challenges.
Image Credit: Wyss institute / Harvard Continue reading
When? This is probably the question that futurists, AI experts, and even people with a keen interest in technology dread the most. It has proved famously difficult to predict when new developments in AI will take place. The scientists at the Dartmouth Summer Research Project on Artificial Intelligence in 1956 thought that perhaps two months would be enough to make “significant advances” in a whole range of complex problems, including computers that can understand language, improve themselves, and even understand abstract concepts.
Sixty years later, and these problems are not yet solved. The AI Index, from Stanford, is an attempt to measure how much progress has been made in artificial intelligence.
The index adopts a unique approach, and tries to aggregate data across many regimes. It contains Volume of Activity metrics, which measure things like venture capital investment, attendance at academic conferences, published papers, and so on. The results are what you might expect: tenfold increases in academic activity since 1996, an explosive growth in startups focused around AI, and corresponding venture capital investment. The issue with this metric is that it measures AI hype as much as AI progress. The two might be correlated, but then again, they may not.
The index also scrapes data from the popular coding website Github, which hosts more source code than anyone in the world. They can track the amount of AI-related software people are creating, as well as the interest levels in popular machine learning packages like Tensorflow and Keras. The index also keeps track of the sentiment of news articles that mention AI: surprisingly, given concerns about the apocalypse and an employment crisis, those considered “positive” outweigh the “negative” by three to one.
But again, this could all just be a measure of AI enthusiasm in general.
No one would dispute the fact that we’re in an age of considerable AI hype, but the progress of AI is littered by booms and busts in hype, growth spurts that alternate with AI winters. So the AI Index attempts to track the progress of algorithms against a series of tasks. How well does computer vision perform at the Large Scale Visual Recognition challenge? (Superhuman at annotating images since 2015, but they still can’t answer questions about images very well, combining natural language processing and image recognition). Speech recognition on phone calls is almost at parity.
In other narrow fields, AIs are still catching up to humans. Translation might be good enough that you can usually get the gist of what’s being said, but still scores poorly on the BLEU metric for translation accuracy. The AI index even keeps track of how well the programs can do on the SAT test, so if you took it, you can compare your score to an AI’s.
Measuring the performance of state-of-the-art AI systems on narrow tasks is useful and fairly easy to do. You can define a metric that’s simple to calculate, or devise a competition with a scoring system, and compare new software with old in a standardized way. Academics can always debate about the best method of assessing translation or natural language understanding. The Loebner prize, a simplified question-and-answer Turing Test, recently adopted Winograd Schema type questions, which rely on contextual understanding. AI has more difficulty with these.
Where the assessment really becomes difficult, though, is in trying to map these narrow-task performances onto general intelligence. This is hard because of a lack of understanding of our own intelligence. Computers are superhuman at chess, and now even a more complex game like Go. The braver predictors who came up with timelines thought AlphaGo’s success was faster than expected, but does this necessarily mean we’re closer to general intelligence than they thought?
Here is where it’s harder to track progress.
We can note the specialized performance of algorithms on tasks previously reserved for humans—for example, the index cites a Nature paper that shows AI can now predict skin cancer with more accuracy than dermatologists. We could even try to track one specific approach to general AI; for example, how many regions of the brain have been successfully simulated by a computer? Alternatively, we could simply keep track of the number of professions and professional tasks that can now be performed to an acceptable standard by AI.
“We are running a race, but we don’t know how to get to the endpoint, or how far we have to go.”
Progress in AI over the next few years is far more likely to resemble a gradual rising tide—as more and more tasks can be turned into algorithms and accomplished by software—rather than the tsunami of a sudden intelligence explosion or general intelligence breakthrough. Perhaps measuring the ability of an AI system to learn and adapt to the work routines of humans in office-based tasks could be possible.
The AI index doesn’t attempt to offer a timeline for general intelligence, as this is still too nebulous and confused a concept.
Michael Woodridge, head of Computer Science at the University of Oxford, notes, “The main reason general AI is not captured in the report is that neither I nor anyone else would know how to measure progress.” He is concerned about another AI winter, and overhyped “charlatans and snake-oil salesmen” exaggerating the progress that has been made.
A key concern that all the experts bring up is the ethics of artificial intelligence.
Of course, you don’t need general intelligence to have an impact on society; algorithms are already transforming our lives and the world around us. After all, why are Amazon, Google, and Facebook worth any money? The experts agree on the need for an index to measure the benefits of AI, the interactions between humans and AIs, and our ability to program values, ethics, and oversight into these systems.
Barbra Grosz of Harvard champions this view, saying, “It is important to take on the challenge of identifying success measures for AI systems by their impact on people’s lives.”
For those concerned about the AI employment apocalypse, tracking the use of AI in the fields considered most vulnerable (say, self-driving cars replacing taxi drivers) would be a good idea. Society’s flexibility for adapting to AI trends should be measured, too; are we providing people with enough educational opportunities to retrain? How about teaching them to work alongside the algorithms, treating them as tools rather than replacements? The experts also note that the data suffers from being US-centric.
We are running a race, but we don’t know how to get to the endpoint, or how far we have to go. We are judging by the scenery, and how far we’ve run already. For this reason, measuring progress is a daunting task that starts with defining progress. But the AI index, as an annual collection of relevant information, is a good start.
Image Credit: Photobank gallery / Shutterstock.com Continue reading
We all have scars, and each one tells a story. Tales of tomfoolery, tales of haphazardness, or in my case, tales of stupidity.
Whether the cause of your scar was a push-bike accident, a lack of concentration while cutting onions, or simply the byproduct of an active lifestyle, the experience was likely extremely painful and distressing. Not to mention the long and vexatious recovery period, stretching out for weeks and months after the actual event!
Cast your minds back to that time. How you longed for instant relief from your discomfort! How you longed to have your capabilities restored in an instant!
Well, materials that can heal themselves in an instant may not be far from becoming a reality—and a family of them known as elastomers holds the key.
“Elastomer” is essentially a big, fancy word for rubber. However, elastomers have one unique property—they are capable of returning to their original form after being vigorously stretched and deformed.
This unique property of elastomers has caught the eye of many scientists around the world, particularly those working in the field of robotics. The reason? Elastomer can be encouraged to return to its original shape, in many cases by simply applying heat. The implication of this is the quick and cost-effective repair of “wounds”—cuts, tears, and punctures to the soft, elastomer-based appendages of a robot’s exoskeleton.
Researchers from Vrije University in Brussels, Belgium have been toying with the technique, and with remarkable success. The team built a robotic hand with fingers made of a type of elastomer. They found that cuts and punctures were indeed able to repair themselves simply by applying heat to the affected area.
How long does the healing process take? In this instance, about a day. Now that’s a lot shorter than the weeks and months of recovery time we typically need for a flesh wound, during which we are unable to write, play the guitar, or do the dishes. If you consider the latter to be a bad thing…
However, it’s not the first time scientists have played around with elastomers and examined their self-healing properties. Another team of scientists, headed up by Cheng-Hui Li and Chao Wang, discovered another type of elastomer that exhibited autonomous self-healing properties. Just to help you picture this stuff, the material closely resembles animal muscle— strong, flexible, and elastic. With autogenetic restorative powers to boot.
Advancements in the world of self-healing elastomers, or rubbers, may also affect the lives of everyday motorists. Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have developed a self-healing rubber material that could be used to make tires that repair their own punctures.
This time the mechanism of self-healing doesn’t involve heat. Rather, it is related to a physical phenomenon associated with the rubber’s unique structure. Normally, when a large enough stress is applied to a typical rubber, there is catastrophic failure at the focal point of that stress. The self-healing rubber the researchers created, on the other hand, distributes that same stress evenly over a network of “crazes”—which are like cracks connected by strands of fiber.
Here’s the interesting part. Not only does this unique physical characteristic of the rubber prevent catastrophic failure, it facilitates self-repair. According to Harvard researchers, when the stress is released, the material snaps back to its original form and the crazes heal.
This wonder material could be used in any number of rubber-based products.
Professor Jinrong Wu, of Sichuan University, China, and co-author of the study, happened to single out tires: “Imagine that we could use this material as one of the components to make a rubber tire… If you have a cut through the tire, this tire wouldn’t have to be replaced right away. Instead, it would self-heal while driving, enough to give you leeway to avoid dramatic damage,” said Wu.
So where to from here? Well, self-healing elastomers could have a number of different applications. According to the article published by Quartz, cited earlier, the material could be used on artificial limbs. Perhaps it will provide some measure of structural integrity without looking like a tattered mess after years of regular use.
Or perhaps a sort of elastomer-based hybrid skin is on the horizon. A skin in which wounds heal instantly. And recovery time, unlike your regular old human skin of yesteryear, is significantly slashed. Furthermore, this future skin might eliminate those little reminders we call scars.
For those with poor judgment skills, this spells an end to disquieting reminders of our own stupidity.
Image Credit: Vrije Universiteit Brussel / Prof. Dr. ir. Bram Vanderborght Continue reading
Millions of years of evolution have allowed animals to develop some elegant and highly efficient solutions to problems like locomotion, flight, and dexterity. As Boston Dynamics unveils its latest mechanical animals, here’s a rundown of nine recent robots that borrow from nature and why.
SpotMini – Boston Dynamics
Starting with BigDog in 2005, the US company has built a whole stable of four-legged robots in recent years. Their first product was designed to be a robotic packhorse for soldiers that borrowed the quadrupedal locomotion of animals to travel over terrain too rough for conventional vehicles.
The US Army ultimately rejected the robot for being too noisy, according to the Guardian, but since then the company has scaled down its design, first to the Spot, then a first edition of the SpotMini that came out last year.
The latter came with a robotic arm where its head should be and was touted as a domestic helper, but a sleeker second edition without the arm was released earlier this month. There’s little detail on what the new robot is designed for, but the more polished design suggests a more consumer-focused purpose.
OctopusGripper – Festo
Festo has released a long line of animal-inspired machines over the years, from a mechanical kangaroo to robotic butterflies. Its latest creation isn’t a full animal—instead it’s a gripper based on an octopus tentacle that can be attached to the end of a robotic arm.
The pneumatically-powered device is made of soft silicone and features two rows of suction cups on its inner edge. By applying compressed air the tentacle can wrap around a wide variety of differently shaped objects, just like its natural counterpart, and a vacuum can be applied to the larger suction cups to grip the object securely. Because it’s soft, it holds promise for robots required to operate safely in collaboration with humans.
CRAM – University of California, Berkeley
Cockroaches are renowned for their hardiness and ability to disappear down cracks that seem far too small for them. Researchers at UC Berkeley decided these capabilities could be useful for search and rescue missions and so set about experimenting on the insects to find out their secrets.
They found the bugs can squeeze into gaps a fifth of their normal standing height by splaying their legs out to the side without significantly slowing themselves down. So they built a palm-sized robot with a jointed plastic shell that could do the same to squeeze into crevices half its normal height.
Snake Robot – Carnegie Mellon University
Search and rescue missions are a common theme for animal-inspired robots, but the snake robot built by CMU researchers is one of the first to be tested in a real disaster.
A team of roboticists from the university helped Mexican Red Cross workers search collapsed buildings for survivors after the 7.1-magnitude earthquake that struck Mexico City in September. The snake design provides a small diameter and the ability to move in almost any direction, which makes the robot ideal for accessing tight spaces, though the team was unable to locate any survivors.
The snake currently features a camera on the front, but researchers told IEEE Spectrum that the experience helped them realize they should also add a microphone to listen for people trapped under the rubble.
Bio-Hybrid Stingray – Harvard University
Taking more than just inspiration from the animal kingdom, a group from Harvard built a robotic stingray out of silicone and rat heart muscle cells.
The robot uses the same synchronized undulations along the edge of its fins to propel itself as a ray does. But while a ray has two sets of muscles to pull the fins up and down, the new device has only one that pulls them down, with a springy gold skeleton that pulls them back up again. The cells are also genetically modified to be activated by flashes of light.
The project’s leader eventually hopes to engineer a human heart, and both his stingray and an earlier jellyfish bio-robot are primarily aimed at better understanding how that organ works.
Bat Bot – Caltech
Most recent advances in drone technology have come from quadcopters, but Caltech engineers think rigid devices with rapidly spinning propellers are probably not ideal for use in close quarters with humans.
That’s why they turned to soft-winged bats for inspiration. That’s no easy feat, though, considering bats use more than 40 joints with each flap of their wings, so the team had to optimize down to nine joints to avoid it becoming too bulky. The simplified bat can’t ascend yet, but its onboard computer and sensors let it autonomously carry out glides, turns, and dives.
Salto – UC Berkeley
While even the most advanced robots tend to plod around, tree-dwelling animals have the ability to spring from branch to branch to clear obstacles and climb quickly. This could prove invaluable for search and rescue robots by allowing them to quickly traverse disordered rubble.
UC Berkeley engineers turned to the Senegal bush baby for inspiration after determining it scored highest in “vertical jumping agility”—a combination of how high and how frequently an animal can jump. They recreated its ability to get into a super-low crouch that stores energy in its tendons to create a robot that could carry out parkour-style double jumps off walls to quickly gain height.
Pleurobot – École Polytechnique Fédérale de Lausanne
Normally robots are masters of air, land, or sea, but the robotic salamander built by researchers at EPFL can both walk and swim.
Its designers used X-ray videos to carefully study how the amphibians move before using this to build a true-to-life robotic version using 3D printed bones, motorized joints, and a synthetic nervous system made up of electronic circuitry.
The robot’s low center of mass and segmented legs make it great at navigating rough terrain without losing balance, and the ability to swim gives added versatility. They also hope it will help paleontologists gain a better understanding of the movements of the first tetrapods to transition from water to land, which salamanders are the best living analog of.
Eelume – Eelume
A snakelike body isn’t only useful on land—eels are living proof it’s an efficient way to travel underwater, too. Norwegian robotics company Eelume has borrowed these principles to build a robot capable of sub-sea inspection, maintenance, and repair.
The modular design allows operators to put together their own favored configuration of joints and payloads such as sensors and tools. And while an early version of the robot used the same method of locomotion as an eel, the latest version undergoing sea trials has added a variety of thrusters for greater speeds and more maneuverability.
Image Credit: Boston Dynamics / YouTube Continue reading
On a dark night, away from city lights, the stars of the Milky Way can seem uncountable. Yet from any given location no more than 4,500 are visible to the naked eye. Meanwhile, our galaxy has 100–400 billion stars, and there are even more galaxies in the universe.
The numbers of the night sky are humbling. And they give us a deep perspective…on drugs.
Yes, this includes wow-the-stars-are-freaking-amazing-tonight drugs, but also the kinds of drugs that make us well again when we’re sick. The number of possible organic compounds with “drug-like” properties dwarfs the number of stars in the universe by over 30 orders of magnitude.
Next to this multiverse of possibility, the chemical configurations scientists have made into actual medicines are like the smattering of stars you’d glimpse downtown.
But for good reason.
Exploring all that potential drug-space is as humanly impossible as exploring all of physical space, and even if we could, most of what we’d find wouldn’t fit our purposes. Still, the idea that wonder drugs must surely lurk amid the multitudes is too tantalizing to ignore.
Which is why, Alex Zhavoronkov said at Singularity University’s Exponential Medicine in San Diego last week, we should use artificial intelligence to do more of the legwork and speed discovery. This, he said, could be one of the next big medical applications for AI.
Dogs, Diagnosis, and Drugs
Zhavoronkov is CEO of Insilico Medicine and CSO of the Biogerontology Research Foundation. Insilico is one of a number of AI startups aiming to accelerate drug discovery with AI.
In recent years, Zhavoronkov said, the now-famous machine learning technique, deep learning, has made progress on a number of fronts. Algorithms that can teach themselves to play games—like DeepMind’s AlphaGo Zero or Carnegie Mellon’s poker playing AI—are perhaps the most headline-grabbing of the bunch. But pattern recognition was the thing that kicked deep learning into overdrive early on, when machine learning algorithms went from struggling to tell dogs and cats apart to outperforming their peers and then their makers in quick succession.
[Watch this video for an AI update from Neil Jacobstein, chair of Artificial Intelligence and Robotics at Singularity University.]
In medicine, deep learning algorithms trained on databases of medical images can spot life-threatening disease with equal or greater accuracy than human professionals. There’s even speculation that AI, if we learn to trust it, could be invaluable in diagnosing disease. And, as Zhavoronkov noted, with more applications and a longer track record that trust is coming.
“Tesla is already putting cars on the street,” Zhavoronkov said. “Three-year, four-year-old technology is already carrying passengers from point A to point B, at 100 miles an hour, and one mistake and you’re dead. But people are trusting their lives to this technology.”
“So, why don’t we do it in pharma?”
Trial and Error and Try Again
AI wouldn’t drive the car in pharmaceutical research. It’d be an assistant that, when paired with a chemist or two, could fast-track discovery by screening more possibilities for better candidates.
There’s plenty of room to make things more efficient, according to Zhavoronkov.
Drug discovery is arduous and expensive. Chemists sift tens of thousands of candidate compounds for the most promising to synthesize. Of these, a handful will go on to further research, fewer will make it to human clinical trials, and a fraction of those will be approved.
The whole process can take many years and cost hundreds of millions of dollars.
This is a big data problem if ever there was one, and deep learning thrives on big data. Early applications have shown their worth unearthing subtle patterns in huge training databases. Although drug-makers already use software to sift compounds, such software requires explicit rules written by chemists. AI’s allure is its ability to learn and improve on its own.
“There are two strategies for AI-driven innovation in pharma to ensure you get better molecules and much faster approvals,” Zhavoronkov said. “One is looking for the needle in the haystack, and another one is creating a new needle.”
To find the needle in the haystack, algorithms are trained on large databases of molecules. Then they go looking for molecules with attractive properties. But creating a new needle? That’s a possibility enabled by the generative adversarial networks Zhavoronkov specializes in.
Such algorithms pit two neural networks against each other. One generates meaningful output while the other judges whether this output is true or false, Zhavoronkov said. Together, the networks generate new objects like text, images, or in this case, molecular structures.
“We started employing this particular technology to make deep neural networks imagine new molecules, to make it perfect right from the start. So, to come up with really perfect needles,” Zhavoronkov said. “[You] can essentially go to this [generative adversarial network] and ask it to create molecules that inhibit protein X at concentration Y, with the highest viability, specific characteristics, and minimal side effects.”
Zhavoronkov believes AI can find or fabricate more needles from the array of molecular possibilities, freeing human chemists to focus on synthesizing only the most promising. If it works, he hopes we can increase hits, minimize misses, and generally speed the process up.
Proof’s in the Pudding
Insilico isn’t alone on its drug-discovery quest, nor is it a brand new area of interest.
Last year, a Harvard group published a paper on an AI that similarly suggests drug candidates. The software trained on 250,000 drug-like molecules and used its experience to generate new molecules that blended existing drugs and made suggestions based on desired properties.
An MIT Technology Review article on the subject highlighted a few of the challenges such systems may still face. The results returned aren’t always meaningful or easy to synthesize in the lab, and the quality of these results, as always, is only as good as the data dined upon.
Stanford chemistry professor and Andreesen Horowitz partner, Vijay Pande, said that images, speech, and text—three of the areas deep learning’s made quick strides in—have better, cleaner data. Chemical data, on the other hand, is still being optimized for deep learning. Also, while there are public databases, much data still lives behind closed doors at private companies.
To overcome the challenges and prove their worth, Zhavoronkov said, his company is very focused on validating the tech. But this year, skepticism in the pharmaceutical industry seems to be easing into interest and investment.
AI drug discovery startup Exscientia inked a deal with Sanofi for $280 million and GlaxoSmithKline for $42 million. Insilico is also partnering with GlaxoSmithKline, and Numerate is working with Takeda Pharmaceutical. Even Google may jump in. According to an article in Nature outlining the field, the firm’s deep learning project, Google Brain, is growing its biosciences team, and industry watchers wouldn’t be surprised to see them target drug discovery.
With AI and the hardware running it advancing rapidly, the greatest potential may yet be ahead. Perhaps, one day, all 1060 molecules in drug-space will be at our disposal. “You should take all the data you have, build n new models, and search as much of that 1060 as possible” before every decision you make, Brandon Allgood, CTO at Numerate, told Nature.
Today’s projects need to live up to their promises, of course, but Zhavoronkov believes AI will have a big impact in the coming years, and now’s the time to integrate it. “If you are working for a pharma company, and you’re still thinking, ‘Okay, where is the proof?’ Once there is a proof, and once you can see it to believe it—it’s going to be too late,” he said.
Image Credit: Klavdiya Krinichnaya / Shutterstock.com Continue reading